{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red107\green107\blue106;
\red14\green86\blue140;
\red33\green33\blue33;
\red249\green250\blue251;
\red204\green204\blue204;
\red228\green231\blue232;
\red119\green119\blue119;
\red80\green80\blue80;
\red37\green37\blue37;
\red247\green247\blue247;
\red151\green151\blue151;
\red21\green137\blue21;
\red246\green246\blue246;
\red51\green51\blue51;
\red56\green124\blue43;
\red254\green254\blue0;
\red0\green114\blue54;
\red106\green144\blue39;
\red181\green79\blue104;
\red112\green112\blue112;
\red255\green255\blue102;
\red214\green214\blue214;
\red187\green187\blue187;
\red232\green233\blue232;
\red249\green249\blue249;
\red255\green248\blue96;
\red239\green122\blue2;
\red255\green255\blue174;
\red204\green255\blue255;
\red255\green255\blue204;
\red255\green204\blue0;
\red203\green203\blue203;
\red245\green245\blue245;
\red229\green243\blue255;
\red179\green218\blue255;
\red240\green240\blue240;
\red20\green93\blue164;
\red105\green105\blue105;
\red227\green227\blue227;
\red188\green41\blue30;
\red190\green237\blue228;
\red238\green238\blue238;
\red233\green233\blue233;
\red61\green61\blue61;
\red218\green218\blue218;
\red227\green232\blue250;
\red70\green70\blue68;
\red250\green250\blue250;
\red255\green194\blue211;
\red236\green236\blue236;
\red183\green242\blue206;
\red127\green127\blue127;
\red71\green120\blue194;
\red102\green0\blue102;
\red182\green231\blue243;
\red190\green190\blue252;
\red120\green162\blue47;
\red251\green252\blue255;
\red72\green72\blue72;
\red190\green195\blue204;
\red153\green153\blue153;
\red214\green9\blue9;
\red102\green102\blue102;
\red185\green185\blue185;
\red240\green248\blue255;
\red223\green223\blue223;
\red239\green239\blue239;
\red255\green255\blue198;
\red172\green172\blue172;
\red9\green56\blue84;
\red118\green118\blue118;
\red153\green255\blue102;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 georgia;}{
\f4 sans-serif;}{
\f5 Source Sans Pro;}{
\f6 serif;}{
\f7 Helvetica;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj \paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Cleveland Clinic Foundation v. True Health Diagnostics, LLC, Not Reported in Fed....
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
}\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 89504e470d0a1a0a0000000d494844520000004e0000000a08030000002dbd985500000300504c5445f8a969f6913ff68931fff9f5f69241f5852af68d38fcddc4f58326fac294f8a868fac193fcdabefab985fcdfc7fef5eef58022f8a35efef6effde5d2fac092fffaf6f9ac6ffffcfafde8d7fef7f1f9b279f6862cf8aa6af79e56f79c53f58327fef1e7fde3cefeeee2f9b076f79a4efef8f4f58123f58224f9ae72feefe4f58021f9ae71fac295fffaf7fcdabffef7f2f9af73f9b177f8ac6ef9b47cf8a15bf6872ef79648fef5edf9b278fcd9bdf9b782f9b57efbc89ffde3cffffefdf6872df8aa6bfcd6b8fac59af9b781fabc8bfffbf8fac091fac396fbceaaf8a461f68e39f6882ffabe8dfabf8ff9b884f79c52fdeadbfeede0f68c36f89f58fcdcc3fde0c9fef0e5fef3eaf68f3cfbcaa2f8a867f9b37afaba87f68b35fde7d6fabf90fffcfbfaba86fde7d5f6903efffdfcfef4ecf68f3bfde1cafcdfc6fbd1affbcea9fcd6b7f68a33f79444fbcba5f58429fcdec6f9af74f8a25df58428f7a461fef4edfdede0fde6d4fde7d4f9b680fbc69cfbc8a0f9b37bfac9a1f69240f79d54fcd4b4f9b883f68e3afef8f3fdebddfde2cbf7984cf8a35ff6882efef3ebf9bd8cfcd4b5feecdef8a562fde6d3fef9f4fcdbc1f9bc8afcd8bcf8ab6dfef8f2fcd7b9fffbf7feefe3f79546f8aa69f79f57fde1cbfcd3b3fcd2b1f8a25cfcd3b2fde2ccfac599fac397f9b379fcd8bbfbd2b0fef2e9fcd5b6fac79ef8a664f8a460f68a32fac090fffbf9fef2e8f8ab6cfde4d0f7994df6903df79749fffefcf79e55f8a766f8a059f68830f7974afde2cdfbcca6fabd8cf57f20ffffff000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000c5baaa8e000000bf74524e53ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff00456e8439000002804944415478da63dcc70001fef2931866b0be0cd2085114e5ff7ef72a0357d0a3a31cc2129ebb9f492a3e4b6eb8cb20913bb5c808a2f849bf610c438bf99a9917cf2a18092c7bf1a30a6a0a13946658f6af92e15352e52386af5d677ee5ff61618c5ca7c6b58921d6ecc47383e56a52b3181955bf2e3e01513b49bae7260383be8b048376a2e34786a3853761a6b0c018892b57313c48fa38834195c1cf94c16a3a03c3edad7c5f163030a8672bcc3afcf4251343639ef3ae2cb05afe384e9390352a0c320cbdf71f19b43d6690c7302e84e11383d28bff67bcba9a6e2831acd9c6e0d990fe70b74ae7d2a90c0cbbc36fbaef6660b80f55ba68e9d2d5a9ae0cdd2f341878be8b9c64f8cb701d660a733c9451af78704effa1c6b3536708cf2c9ffde7c78fcb9b16497b8acf3e3721061812bfde8433302c8d5a190152ca93f7d26df6796bff83310dbfe504de7f7ff9ec621c7ad8ade964d5f0f8162da4257e9da18c39434955602283a37fdaefde9cb30c686005c3a4c9a6d792186c6b665d8e54f97ae7c5badd189e65307c22395565fbc43fcc010cad5b3ba781c5363184af0bfa8530481844b84e65b87efde6bcb50c67d9dc36d4f6bf7aa6e4015700771dc3fd57751f183c97ecfe7f04c8b17e9f9fdfceb0e334c3ca37c16940feb644b09ad7e1aee90cdaaa9f1ca31ef6bd6478e2b43ba29f615fc7cf550c1861c720c2699619c930d362d55a060ff68e592f7d4eacd82df9eb3bd7bd387986ff73182d18183686ba2ff9f76ec59f909c2e83a8499dbbaaa404ecf8199cb8051e79627ad6fa4799360383602cd0bdcbdeb2fc6158debec577daf1a9076ba51818e679bf05aaf85cfdeb0f8383c1ec0973801cee342386c537cdf218fecf4b70801b0200f61ff095f54de6170000000049454e44ae426082}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_54}{\*\bkmkend co_document_54}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart Idce34d30dac311e581b4a1a364f337cb_Target}{\*\bkmkend Idce34d30dac311e581b4a1a364f337cb_Target}
\par 
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb100 
2016 WL 705244
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Only the Westlaw citation is currently available.
\par 
}
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States District Court, N.D. Ohio, Eastern Division.
\par 
}
}
}
{\b0 \qc \cf27 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf27 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf27 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf27 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
The CLEVELAND CLINIC FOUNDATION, et al., Plaintiff,
\par 
}
}
{\b0 \qc \cf27 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf27 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf27 \f3 \ri120 \i0 \fs24 \li120 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5046704989)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
TRUE HEALTH DIAGNOSTICS, LLC
}}}
{\b0 \cf27 \f3 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
, Defendant.
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
CASE NO. 1:15 CV 2331
\par 
}
}
}
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Signed 02/23/2016
\par 
}
}
}
}
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_54}{\*\bkmkend co_attorneysAndLawFirms_54}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0485701801&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Joshua A. Friedman
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0199966101&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Todd R. Tucker
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Calfee, Halter & Griswold, Cleveland, OH, for Plaintiff.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0337247201&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Adam L. Marchuk
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0474361801&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Caroline A. Teichner
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0422215101&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Mark T. Smith
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0321413601&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Michael R. Osterhoff
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Perkins Coie, Chicago, IL, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0466373901&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
David Sporar
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Brouse McDowell, Cleveland, OH, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0385311901&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Kerri L. Keller
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Brouse McDowell, Akron, OH, for Defendant.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_54}{\*\bkmkend co_opinion_54}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifaebad35377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifaebad35377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifaf4fc01377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifaf4fc01377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb600 
Memorandum of Opinion and Order
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0152496001&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
PATRICIA A. GAUGHAN
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, United States District Judge
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifaf52311377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifaf52311377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifaf52311377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifaf52311377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
INTRODUCTION
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_1_54}{\*\bkmkend co_pp_sp_999_1_54}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 This matter is before the Court upon the Motion of Defendant True Health Diagnostics LLC to Dismiss (Doc. 25). This is a patent infringement case. For the reasons that follow, the motion is GRANTED.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012038337569_ID0E5BAC_54}{\*\bkmkend co_fnRef_B00012038337569_ID0E5BAC_54}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012038337569_54" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifaf5e661377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifaf5e661377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifaf5e661377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifaf5e661377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
FACTS
}
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022038337569_ID0EPDAC_54}{\*\bkmkend co_fnRef_B00022038337569_ID0EPDAC_54}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022038337569_54" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiffs, The Cleveland Clinic Foundation (\u8220\'3fCCF\u8221\'3f) and Cleveland HeartLab (\u8220\'3fHeartLab\u8221\'3f) (CCF and Heartlab, sometimes, collectively \u8220\'3fplaintiff\u8221\'3f) filed this lawsuit against defendant, True Health Diagnostics. In 2003, researchers at CCF developed a test that assesses a patient\rquote s risk for 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fCVD\u8221\'3f). The test, called Myeloperoxidase or \u8220\'3fMPO\u8221\'3f testing, analyzes inflammation of the blood vessels. MPO is an enzyme released by white blood cells when inflammation occurs in the body. When an artery wall is damaged or becomes inflamed, MPO is released into the blood stream in an effort to kill bacteria. Thus, MPO is an early symptom of many types of CVD.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
CCF filed a series of patent applications relating to MPO. The Patent and Trademark Office (\u8220\'3fPTO\u8221\'3f) granted CCF\rquote s applications, and it is currently the owner of the four patents at issue in this lawsuit: 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,223,552 (\u8220\'3fthe \lquote 552 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,459,286 (\u8220\'3fthe \lquote 286 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 8,349,581 (\u8220\'3fthe \lquote 581 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 9,170,260 (\u8220\'3fthe \lquote 260 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which issued on May 29, 2007, has since been the subject of validity challenges by competitors in two reexamination proceedings before the PTO. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was confirmed valid in both proceedings, most recently in 2011.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 286 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 581 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 teach a method of analyzing MPO biomarkers in a patient\rquote s blood sample
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00032038337569_ID0EKIAC_54}{\*\bkmkend co_fnRef_B00032038337569_ID0EKIAC_54}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00032038337569_54" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to predict a patient\rquote s potential for CVD. They do so by comparing the level of MPO found in the patient\rquote s blood sample with levels of MPO in control subjects to see if the patient has elevated levels of MPO. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does so with regard to a typical patient, while the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 286 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 581 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are directed at patients presenting with chest pain.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 issued after the filing of this lawsuit. Plaintiff filed an amended complaint to add a claim of infringement regarding this newly issued patent. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 teaches a method for administering a lipid lowering agent based on elevated levels of MPO. In addition, the amended complaint added a claim for infringement of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037437187&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=Ib0ff98e0797a11e5b3b0cdc939ec592d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 9,164,095 (\u8220\'3fthe \lquote 095 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which also issued after the filing of this lawsuit.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_2_54}{\*\bkmkend co_pp_sp_999_2_54}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*2
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Shortly after filing the amended complaint, plaintiff voluntarily dismissed count four, which asserted infringement based on the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037437187&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=Ib0ff98e0797a11e5b3b0cdc939ec592d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 095 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Each of the four remaining claims assert a claim for infringement for each of the remaining patents. The Court previously denied plaintiff\rquote s motion for a temporary restraining order and preliminary injunction. Defendant now moves to dismiss this lawsuit and plaintiff opposes the motion.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifaf8cc91377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifaf8cc91377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifaf8cc91377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifaf8cc91377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
STANDARD OF REVIEW
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
When considering a motion to dismiss pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6) of the Federal Rules of Civil Procedure
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the allegations of the complaint must be taken as true and construed liberally in favor of the plaintiff. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999201173&pubNum=0000506&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_506_691&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_691" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Lawrence v. Chancery Court of Tenn., 
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
188 F.3d 687, 691 (6th Cir. 1999)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Notice pleading requires only that the defendant be given \u8220\'3ffair notice of what the plaintiff\rquote s claim is and the grounds upon which it rests.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1957120403&pubNum=0000780&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_780_47&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_47" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Conley
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 355 U.S. at 47
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. However, the complaint must set forth \u8220\'3fmore than the bare assertion of legal conclusions.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1993095894&pubNum=0000350&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_350_1240&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1240" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Allard v. Weitzman
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In Re DeLorean Motor Co.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
), 991 F.2d 1236, 1240 (6th Cir. 1993)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Legal conclusions and unwarranted factual inferences are not accepted as true, nor are mere conclusions afforded liberal 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 review. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1996262508&pubNum=0000506&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Fingers v. Jackson-Madison County General Hospital District, 
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101 F.3d 702 (6th Cir. Nov. 21, 1996)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
 unpublished
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Dismissal is proper if the complaint lacks an allegation regarding a required element necessary to obtain relief. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1990055865&pubNum=0000350&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_350_489&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_489" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Craighead v. E.F. Hutton & Co., 
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
899 F.2d 485, 489-490 (6th Cir. 1990)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In addition, a claimant must provide \u8220\'3fenough facts to state a claim to relief that is plausible on its face.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012293296&pubNum=0000780&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_780_569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_569" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bell Atlantic Corp. v. Twombly
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 550 U.S. 544, 569 (2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. A pleading that offers \u8220\'3flabels and conclusions\u8221\'3f or \u8220\'3fa formulaic recitation of the elements of a cause of action will not do.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018848474&pubNum=0000708&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_708_1955&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1955" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ashcroft v. Iqbal
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 129 S.Ct. 1937, 1955 (2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Nor does a complaint suffice if it tenders \u8220\'3fnaked assertion[s]\u8221\'3f devoid of \u8220\'3ffurther factual enhancement.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to state a claim to relief that is plausible on its face. A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged. The plausibility standard is not akin to a \u8220\'3fprobability requirement,\u8221\'3f but it asks for more than a sheer possibility that a defendant has acted unlawfully. Where a complaint pleads facts that are \u8220\'3fmerely consistent with\u8221\'3f a defendant\rquote s liability, it stops short of the line between possibility and plausibility of \u8216\'3fentitlement to relief.\u8217\'3f
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at 1949 (citations and quotations omitted). 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See also, 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019737337&pubNum=0000506&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Hensley Mfg. v. ProPride, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 579 F.3d 603 (6th Cir.2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifafb1681377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifafb1681377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifafb1681377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifafb1681377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
ANALYSIS
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifafb1681377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifafb1681377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
1. Preliminary issues
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
A. Timing and burden of proof
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As an initial matter, the Court finds that it is procedurally proper to address defendant\rquote s arguments concerning invalidity based on patent-eligibility at the 12(b)(6) stage. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035137097&pubNum=0000506&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Content Extraction and Transmission, LLC v. Wells Fargo National Bank Association
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 776 F.3d 1343 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In addressing defendant\rquote s arguments, the Court will presume that the patents are valid and grant the motion only if defendant is able to show invalidity by clear and convincing evidence. Although post-
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 courts appear to call into question whether a presumption of validity applies in this context, the Court will nonetheless apply the presumption.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_3_54}{\*\bkmkend co_pp_sp_999_3_54}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*3
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court rejects plaintiff\rquote s argument that the Court cannot address these issues before claim construction. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032785610&pubNum=0006538&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_6538_991&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_6538_991" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cyberfone Sys. LLC v. CNN Interactive Group, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 558 Fed. Appx. 988, 991 n.1 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. For purposes of this motion, defendant indicates that it is willing to accept plaintiff\rquote s proposed claim construction. In connection with its motion for temporary restraining order and preliminary injunction, plaintiff argued to the Court that \u8220\'3f[e]xcept for \u8220\'3fMPO Activity\u8221\'3f and \u8220\'3fMPO Mass,\u8221\'3f all of the claim terms should simply be afforded their plain and ordinary meaning.\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 In its brief in opposition to the instant motion, plaintiff indicates that it is 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
now
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 apparent that additional terms need construction. Those terms include \u8220\'3fimmunological technique,\u8221\'3f \u8220\'3fcomparing levels,\u8221\'3f and \u8220\'3fdetermining levels.\u8221\'3f Yet, plaintiff offers no proposed construction for these terms. Defendant has stipulated for purposes of this motion to plaintiff\rquote s proposed claim construction, yet plaintiff offers none with regard to these terms. Plaintiff\rquote s failure will not serve to block the Court from considering defendant\rquote s motion. Otherwise, a plaintiff could prevent dismissal before claim construction simply by noting without explanation that claim construction is \u8220\'3fnecessary.\u8221\'3f The Court rejects any such rule.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifaffaa61377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifaffaa61377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
B. Representative claims
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court further rejects plaintiff\rquote s argument that the Court must address each claim in each patent separately. Defendant argues that claims 11, 14, and 15 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are representative of the remaining claims. Similarly, defendant argues that claims 21 and 22 are representative of the claims in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 286 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claim 5 is representative of the claims in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 581 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Defendant notes that with the exception of claim 14 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, plaintiff\rquote s motion for temporary restraining order and preliminary injunction was based solely on these claims. Moreover, plaintiff fails to point out any claim that is not represented by the aforementioned claims. Rather, plaintiff simply argues:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Importantly in this regard, no one asserted claim is representative of the others. Some claims require \u8220\'3fdetermining levels\u8221\'3f while others claim \u8220\'3fcomparing levels.\u8221\'3f Some of the dependent claims contain limitations, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, \u8220\'3fimmunological technique,\u8221\'3f that further ground those claims as patentable subject matter. These limitations each add additional inventive matter, and thus must each be separately considered.
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As defendant notes, however, the representative claims do include the \u8220\'3fdetermining\u8221\'3f and \u8220\'3fcomparing\u8221\'3f limitations referenced by plaintiff. Moreover, to the extent dependent claims 7 and 23 contain the \u8220\'3fimmunological technique,
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00042038337569_ID0E1LAE_54}{\*\bkmkend co_fnRef_B00042038337569_ID0E1LAE_54}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00042038337569_54" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
4
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8221\'3f the Court will address the limitation below. As such, the Court finds that the claims identified by defendant are representative of the claims in the patents in suit.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifb017f21377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifb017f21377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
C. Claim language
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claims 11, 14, and 15 in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 provide as follows:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
11. A method for assessing a test subject\rquote s risk of having 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
comparing levels of myeloperoxidase in a bodily sample from the test subject with levels of myeloperoxidase in comparable bodily samples from control subjects diagnosed as not having the disease, said bodily sample being blood, serum, plasma, blood 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iadf4fbaa475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
leukocytes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 selected from the group consisting of neutrophils, monocytes, subpopulations of neutrophils, and subpopulations of monocytes, or any combination thereon;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
wherein elevated levels of myeloperoxidase in the bodily sample from the test subject relative to the levels of myeloperoxidase in the comparable bodily samples from control subjects is indicative of the extent of the test subject\rquote s risk of having 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
14. A method of assessing a test subject\rquote s risk of developing a complication of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
determining levels of myeloperoxidase (MPO) activity, myeloperoxidase (MPO) mass, or both in a bodily sample of the test subject, said bodily sample being blood, serum, plasma, blood 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iadf4fbaa475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
leukocytes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 selected from the group consisting of neutrophils and monocytes, or any combination thereof;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_4_54}{\*\bkmkend co_pp_sp_999_4_54}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*4
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 wherein elevated levels of MPO activity or MPO mass or both in the subject\rquote s bodily sample as compared to levels of MPO activity, MPO mass or both, respectively, in comparable bodily samples obtained from control subjects diagnosed as not having the disease indicates that the test subject is at risk of developing a complication of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
15. The method of claim 14, wherein the test subject\rquote s risk of developing a complication of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 is determined by comparing levels of myeloperoxidase mass in the test subject\rquote s bodily sample to levels of myeloperoxidase mass in comparable samples obtained from the control subjects.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claims 21 and 22 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 286 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 provide as follows:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
21. A method of assessing the risk of requiring medical intervention in a patient who is presenting with chest comprising
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
characterizing the levels of myeloperoxidase activity, myeloperoxidase mass, or both, respectively in the bodily sample from the human patient, wherein said bodily sample is blood or a blood derivative,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein a patient whose levels of myeloperoxidase activity, myeloperoxidase mass, or both is characterized as being elevated in comparison to levels of myeloperoxidase activity, myeloperoxidase mass or both in a comparable bodily samples obtained from individuals in a control population is at risk of requiring medical intervention to prevent the occurrence of an adverse cardiac event within the next six months.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
22. A method of determining whether a patient who presents with chest pain is at risk of requiring medical intervention to prevent an adverse cardiac event within the next six months comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
comparing the level of a risk predictor in a bodily sample from the subject with a value that is based on the level of said risk predictor in comparable samples from a control population, wherein said risk predictor is myeloperoxidase activity, myeloperoxidase mass, a myeloperoxidase-generated oxidation product, or any combination thereof, and wherein said bodily sample is blood, serum, plasma, or urine,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein a subject whose bodily sample contains elevated levels of said risk predictor as compared to the control value is at risk of requiring medical intervention to prevent an adverse cardiac event within 6 months of presenting with chest pain, and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein the difference between the level of the risk predictor in the patient\rquote s bodily sample and the level of the risk predictor in a comparable bodily sample from the control population establishes the extent of the risk to the subject of requiring medical intervention to prevent an adverse cardiac event within the next six months.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 5 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 581 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 provides as follows:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
5. A method of determining whether a patient who presents with chest pain is at risk of requiring medical intervention to prevent an adverse cardiac event within the next six months comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
determining the level of risk predictor in a bodily sample from the subject, wherein said risk preddictor is myeloperoxidase activity, myeloperoxidase mass, a myeloperoxidase (MPO)-generated oxidation product or any combination thereof,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein said bodily sample is blood, serum, plasma or urine,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_5_54}{\*\bkmkend co_pp_sp_999_5_54}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*5
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 wherein said myeloperoxidase-generated oxidation product is nitrotyrosine or a myeloperoxidase-generated lipid peroxidation product selected from [list of products]...or any combination thereof, and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
comparing the level of said risk predictor in the bodily sample of the patient to the level of said risk predictor in comparable samples obtained from a control population,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein a subject whose bodily sample contains elevated levels of said risk predictor as compared to the control value is at risk of requiring medical intervention to prevent an adverse cardiac event within 6 months of presenting with chest pain.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifb07e7c1377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifb07e7c1377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifb07e7c1377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifb07e7c1377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
2. Invalidity
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Defendant argues that three of the four remaining patents in this lawsuit are invalid. According to defendants, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 286 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 581 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are invalid for ineligible subject matter. According to defendant, these patents are directed at a law of nature and contain no inventive step. Plaintiff disagrees.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, [w]hoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefore....\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is limited, however, and does not cover \u8220\'3flaws of nature, natural phenomena, and abstract ideas.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corp. Pty. Ltd v. CLS Bank International
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. 2347, 2354 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In \u8220\'3fapplying the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 exception, we must distinguish between patents that claim the \u8216\'3fbuilding block[s]\u8217\'3f of human ingenuity and those that integrate the building blocks into something more.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
citing 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_708_1303&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1303" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Services v. Prometheus Laboratories, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. 1289, 1303 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court employed a two-part test \u8220\'3ffor distinguishing patents that claim laws of nature, natural phenomena, and abstract ideas from those that claim patent-eligible applications of those concepts.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Courts must tread carefully because \u8220\'3fat some level, all inventions...embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at 2354
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. First, the court must determine \u8220\'3fwhether the claims at issue are directed at a patent-ineligible concept.\u8221\'3f If the claims are so directed, the Court must proceed to step two, which involves a determination as to whether the patent contains an \u8220\'3finventive concept,\u8221\'3f which is described as \u8220\'3fan element or combination of elements that is sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the ineligible concept itself.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (Internal citations and quotations omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court addressed the validity of a patent designed to \u8220\'3fhelp doctors who use thiopurine drugs to treat patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic39e7bac475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
autoimmune diseases
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 determine whether a given dosage level is too low or too high.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_708_1294&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1294" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
132 S.Ct. at 1294
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Specifically, the patent described a process of evaluating the safety of the concentrations of a particular metabolite in a person\rquote s blood. The Federal Circuit determined that in addition to the natural correlations, the patent claimed specific steps of administering a thiopourine drug and determining the resulting metabolite level. As such, the Federal Circuit determined that the patent was directed at patent-eligible subject matter. The Supreme Court reversed, finding:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_6_54}{\*\bkmkend co_pp_sp_999_6_54}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*6
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 To put the matter more succinctly, the claims inform a relevant audience about certain laws of nature; any additional steps consist of well-understood, routine, conventional activity already engaged in by the scientific community; and those steps, when viewed as a whole, add nothing significant beyond the sum of their parts taken separately.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at 1298.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
With regard to the first prong of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 test, the Court finds that the patents at issue are directed at a law of nature. Defendant claims that the patents recite the relationship between MPO levels in the bloodstream and the risk of having or developing CVD. Plaintiff does not respond to this argument. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Upon review, the Court agrees with the defendant that the patents at issue are directed at a natural law, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the correlation between MPO in the blood and the risk of CVD.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The second step in the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 test requires the Court to determine whether the patents contain an \u8220\'3finventive concept,\u8221\'3f which is described as \u8220\'3fan element or combination of elements that is sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the ineligible concept itself.\u8221\'3f Upon review, the Court finds that the patents do not satisfy step two.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 581 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 contain a \u8220\'3fdetermining\u8221\'3f step. That step, however, simply calls for determining the MPO mass or activity level from the blood sample by whatever method the user chooses. As defendant notes, a myriad of methods well-known in the art existed at the time of invention. The patents themselves acknowledge that such well-known techniques existed. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 8:32-33 (\u8220\'3f[MPO] activity may be determined by any of a variety of standard methods known in the art.\u8221\'3f) Thus, the \u8220\'3fdetermining\u8221\'3f step does not add an inventive concept.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Similarly, the \u8220\'3fcomparing\u8221\'3f step is insufficient to satisfy the
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
 Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 test. As an initial matter, this step involves a mental process, which does not add an inventive step. This step simply requires comparing the MPO mass or activity level in the test subject to the level in a control population. The control samples are in turn derived from basic statistical techniques and can vary in form. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 21:11-29. The Court finds that this step does not add an inventive concept. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029241057&pubNum=0006538&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
PerkinElmer, Inc. v. Intema Ltd.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 496 Fed. Appx. 65 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(\u8220\'3fcomparing\u8221\'3f step is an ineligible mental process where the statistical information was well-understood, conventional information).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Furthermore, looking at the claims as a whole, the steps in combination do not make the ineligible mental steps and natural law patent-eligible.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00052038337569_ID0EDHAG_54}{\*\bkmkend co_fnRef_B00052038337569_ID0EDHAG_54}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00052038337569_54" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
5
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Here, like the claims at issue in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
PerkinElmer
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, do not require that a doctor act on any risk. Rather, the steps in combination simply instruct a user to apply a natural law, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, that an increase in MPO mass or MPO activity in a blood sample correlates to an increase in CVD risk.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiff argues that the prosecution history shows that the patents-in-suit claim a non-routine way of measuring and using MPO to achieve a new and useful result. According to plaintiff, it invented a specific way to \u8220\'3fsee\u8221\'3f MPO. Rather than rely on the myeloperoxidase intracelleular index (\u8220\'3fMPXI\u8221\'3f), plaintiff\rquote s patents allow for \u8220\'3fnew measurement\u8221\'3f techniques, namely using \u8220\'3fMPO mass\u8221\'3f and \u8220\'3fMPO activity\u8221\'3f to detect CVD. Upon review, the Court disagrees. As defendant notes, plaintiff defines \u8220\'3fMPO activity\u8221\'3f to mean \u8220\'3fthat a substrate is provided to assess the enzymatic activity of the MPO.\u8221\'3f Similarly, \u8220\'3fMPO mass\u8221\'3f means the amount of MPO molecules in a sample, measured, for example, in picomoles per liter (pmol/L).\u8221\'3f In other words, these terms refer to naturally occurring measurements, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, enzymatic activity level and amount of MPO molecules. Thus, even assuming plaintiff was the first to discover that the amount of MPO molecules in blood or the enzymatic activity level in the MPO can be correlated to CVD, this does not amount to an \u8220\'3finventive\u8221\'3f step.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00062038337569_ID0ETJAG_54}{\*\bkmkend co_fnRef_B00062038337569_ID0ETJAG_54}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00062038337569_54" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
6
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 As noted in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Association for Molecular Pathology v. Myriad Genetics
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 133 S.Ct. 2107 (2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3f [g]roundbreaking, innovative, or even brilliant discovery does not by itself satisfy the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 inquiry.\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Thus, even though plaintiff may have been the first to \u8220\'3fsee\u8221\'3f MPO by looking at the amount of MPO molecules and/or the enzymatic activity level, these values are naturally occurring and their discovery does not render the patents eligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (\u8220\'3fDiscovering important and useful gene and separating it from its surrounding genetic material is not an act of invention.\u8221\'3f). 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See also, 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa Diagnostics, Inc v. Sequenom, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d 1371 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(as it is undisputed that cffDNA is naturally located in maternal blood, the fact that plaintiffs were the first to \u8220\'3fsee\u8221\'3f it does not in and of itself satisfy 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_7_54}{\*\bkmkend co_pp_sp_999_7_54}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*7
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Plaintiff repeatedly argues that the PTO issued the patents and, therefore, they must contain an inventive concept. Plaintiff points out that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was reexamined twice and the PTO determined that measuring MPO with MPXI was the prior conventional approach for detecting MPO and that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims \u8220\'3fnon-routine techniques that could measure MPO in a different way.\u8221\'3f For the aforementioned reasons, the Court rejects plaintiff\rquote s argument. The fact that the PTO issued the patent is not sufficient, standing alone, to satisfy 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. All of the patents challenged in invalidity proceedings were issued by the PTO and presumably the PTO found them \u8220\'3fdifferent from\u8221\'3f and \u8220\'3fimprovements over\u8221\'3f prior art. Plaintiff points to nothing in the prosecution history showing that the PTO addressed 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiff also argues that certain dependent claims contain an inventive step because they call for the use of an \u8220\'3fimmunological technique.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, claims 7 and 23 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) Plaintiff initially argues that this term requires construction, yet provides the Court with no proposed construction. As set forth above, plaintiff\rquote s failure in this regard will not prevent the Court from addressing defendant\rquote s motion to dismiss. Nor does plaintiff provide any specific argument as to why the inclusion of an \u8220\'3fimmunological technique\u8221\'3f satisfies 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. On the other hand, defendant argues that this limitation does not amount either singularly or in combination with other limitations to an inventive concept because it simply instructs that the levels of MPO mass are \u8220\'3fdetermined by an immunological technique.\u8221\'3f The Court agrees with defendant that this does not add an inventive step. The patent identifies that one type of immunological technique is ELISA and \u8220\'3fcommercial kits for MPO quantification are available.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 9:30-33. Regardless, in the face of defendant\rquote s position to the contrary, plaintiff offers no argument as to why the inclusion of an \u8220\'3fimmunological technique\u8221\'3f satisfies 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Accordingly, any such argument is rejected.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00072038337569_ID0ENTAG_54}{\*\bkmkend co_fnRef_B00072038337569_ID0ENTAG_54}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00072038337569_54" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
7
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiff argues that the patent satisfies 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because it does not preempt the entire field since it does not foreclose the use of other current or future MPO measuring techniques. The argument is rejected. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_506_1379&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1379" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa Diagnostics
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d at 1379
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fWhere a patent\rquote s claims are deemed only to disclose patent ineligible subject matter under the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 framework, as they are in this case, preemption concerns are fully addressed and made moot.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifb110f81377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifb110f81377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifb110f81377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifb110f81377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
3. Sufficiency of the allegations
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In count five, plaintiff asserts a claim for indirect infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Defendant argues that count five fails to state a claim for indirect infringement based on either contributory or induced infringement. In response, plaintiff argues that the allegations are sufficient and, in the alternative, requests leave to amend the claim.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifb1184b1377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifb1184b1377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
A. Contributory infringement
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Upon review, the Court finds that the complaint fails to state a claim for contributory infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_4b24000003ba5" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fContributory infringement occurs if a party sells or offers to sell, a material or apparatus for use in practicing a patented process, and that \lquote material or apparatus\rquote  is material to practicing the invention, has no substantial non-infringing uses, and is known by the party to be especially made or especially adapted for use in an infringement of such patent.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027859004&pubNum=0000506&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_506_1337&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1337" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re Bill of Lading Transmission & Processing Sys. Patent Litig.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 681 F.3d 1323, 1337 (Fed.Cir.2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fUnder the plain language of the statute, a person who provides a service that assists another in committing patent infringement may be subject to liability under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section 271(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for active inducement of infringement, but not under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_4b24000003ba5" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section 271(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for contributory infringement.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012652319&pubNum=0000506&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_506_1357&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1357" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
PharmaStem Therapeutics, Inc. v. ViaCell, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 491 F.3d 1342, 1357 (Fed. Cir. 2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_8_54}{\*\bkmkend co_pp_sp_999_8_54}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*8
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court agrees with defendant that the complaint does not state a claim for contributory infringement because plaintiff fails to identify any \u8220\'3fmaterial or apparatus\u8221\'3f sold by defendant. Plaintiff argues that it identifies and attaches to its complaint five lab-reports, which plaintiff claims constitute a \u8220\'3fmaterial or apparatus\u8221\'3f for purposes of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_4b24000003ba5" }{\fldrslt 
{\b1 \cf27 \f2 \i0 \fs20 \chcbpat39 
{\b1 \cf27 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Court disagrees. To the contrary, plaintiff expressly alleges that defendant purchases (as opposed to sells) the MPO testing kits. (Doc. 20 at \u182\'3f 30). Plaintiff further alleges that defendant infringes by \u8220\'3fusing MPO test kits and performing and/or selling MPO testing services.\u8221\'3f (Doc. 20 at \u182\'3f\u182\'3f 39, 45). At best, the lab reports attached to the complaint reflect the manner in which defendant reports the results of the service it provides. The Court finds that, based on the allegations in the complaint, the lab reports do not constitute a \u8220\'3fmaterial or apparatus\u8221\'3f for purposes of a contributory infringement claim. Having failed to allege this element of the claim, the Court agrees with defendant that dismissal is warranted.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifb12e441377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifb12e441377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
B. Induced infringement
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section 271(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, whoever actively induces infringement of a patent shall be liable as an infringer. To establish liability under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section 271(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
, a patent holder must prove that once the defendants knew of the patent, they actively and knowingly aided and abetted another\rquote s direct infringement. However, knowledge of the acts alleged to constitute infringement is not enough. The mere knowledge of possible infringement by others does not amount to inducement; specific intent and action to induce infringement must be proven.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2010878868&pubNum=0000506&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
DSU Medical Corp. v. JMS Co. Ltd.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 471 F.3d 1293 (Fed. Cir. 2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(internal citations and quotations omitted). Here, defendant argues that plaintiff fails to state a claim for induced infringement because there are no facts supporting plaintiff\rquote s bare allegations that defendant \u8220\'3fintended that its actions would induce direct infringement by others\u8221\'3f or that defendant \u8220\'3fknew or should have known that its actions would induce direct infringement by others.\u8221\'3f
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In response, plaintiff argues that the complaint sufficiently alleges that defendant had knowledge of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. According to plaintiff, defendant purchased some of the assets of Health Diagnostics Lab (\u8220\'3fHDL\u8221\'3f) in a bankruptcy proceeding. In its bid for HDL\rquote s assets, defendant sought HDL\rquote s customer list, including HDL\rquote s MPO testing customers, but expressly excluded HDL\rquote s Laboratory Services Agreement with HeartLab. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Thereafter, HeartLab\rquote s CEO emailed defendant on September 14, 2015, to advise defendant regarding the patents. The letter provides as follows:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
We understand that you intend on rejecting our contract as part of the conclusion of your asset purchase, however please be advised that although the terms of our agreement may be rejected, our intellectual property rights are not something that can be rejected in a bankruptcy or 363 asset sale process. For background, many of our patents are referenced in Section 7 of our LSA that is referenced in the attached letter. There are multiple issued patents on MPO in our patent family as well as additional patents pending and this IP has been successfully defended multiple times in re-examination. It is also important to know that these are Cleveland Clinic patents and they have an obligation to protect them.
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This email was sent before the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 issued. Plaintiff also points out that the Laboratory Services Agreement identified the \lquote 799 application, which plaintiff claims became the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Plaintiff further notes that in the context of this litigation, defense counsel acknowledged investigating the \lquote 381 application, which is a continuation of the \lquote 799 application. Therefore, plaintiff claims that the allegations in the complaint are sufficient to meet the knowledge requirement.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court finds that assuming 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
arguendo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that the aforementioned allegations are sufficient to meet the pleading requirements with regard to the knowledge of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Court finds that the complaint nonetheless fails to sufficiently allege a claim for induced infringement. As defendant notes, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
in addition 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
to knowledge, plaintiff must allege sufficient factual support to meet the specific intent element:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_9_54}{\*\bkmkend co_pp_sp_999_9_54}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*9
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 Beyond that threshold knowledge, the inducer must have an affirmative intent to cause direct infringement....[I]nducement requires that the alleged infringer knowingly induced infringement and possessed specific intent to encourage another\rquote s infringement. Accordingly, inducement requires evidence of culpable conduct, directed to encouraging another\rquote s infringement, not merely that the inducer had knowledge of the direct infringer\rquote s activities.\u8221\'3f
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
DSU Medical Corp.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 471 F.3d at 306. (Citations and quotations omitted). Moreover, \u8220\'3fmere knowledge of possible infringement by others does not amount to inducement; specific intent and action to induce infringement must be proven.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. at 1305.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, plaintiff does not respond to defendant\rquote s argument that the complaint fails to allege facts sufficient to show the specific intent to induce a third-party to infringe. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is a method patent directed at \u8220\'3fadministering a lipid lowering agent to a human patient based on elevated levels of [MPO] mass and/or activity comprising...\u8221\'3f Thus, in generic terms, the third-party direct infringer must administer a lipid lowering agent based on elevated levels of MPO in order to infringe the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Although the complaint is devoid of any factual allegations regarding the relationship between defendant and these \u8220\'3fthird party infringers,\u8221\'3f it appears to the Court that the third-party infringers are the doctors that order the testing. Thus, in order to be liable, plaintiff must sufficiently allege that defendant specifically intends to induce doctors to administer a lipid lowering agent based on elevated levels of MPO. The complaint is completely devoid of any factual allegations supporting this theory. In fact, the complaint contains no allegations even generally describing defendant\rquote s alleged role in the infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or any manner in which defendant induces such infringement.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00082038337569_ID0EIGBG_54}{\*\bkmkend co_fnRef_B00082038337569_ID0EIGBG_54}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00082038337569_54" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
8
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 As such, the Court finds that plaintiff does not allege sufficient facts to satisfy the specific intent element of an inducement claim. Having concluded that plaintiff fails in this regard, the Court need not reach whether plaintiff adequately alleges an act of direct infringement.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court notes that plaintiff alternatively seeks leave to amend its complaint in the event the claim is dismissed. The Court denies plaintiff\rquote s request. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004349872&pubNum=0000506&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=RP&fi=co_pp_sp_506_699&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_699" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
PR Diamonds, Inc. v. Chandler
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 364 F.3d 671, 699 (6th Cir. 2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifb179f31377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifb179f31377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ifb179f31377611ebb3b3bf06073c7}{\*\bkmkend co_anchor_Ifb179f31377611ebb3b3bf06073c7}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
CONCLUSION
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For the foregoing reasons, the Motion of Defendant True Health Diagnostics LLC to Dismiss (Doc. 25) is GRANTED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
IT IS SO ORDERED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_54}{\*\bkmkend co_allCitations_54}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Not Reported in Fed. Supp., 2016 WL 705244
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012038337569_54}{\*\bkmkend co_footnote_B00012038337569_54}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012038337569_ID0E5BAC_54" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Plaintiff\rquote s request for judicial notice is GRANTED in PART and DENIED in PART. The Court will take judicial notice of the patent prosecution history excerpts and the prior art identified by plaintiff. The Court cannot, however, take judicial notice of the facts contained in the \u8220\'3fTRO motion and its supporting papers.\u8221\'3f Simply because a particular fact is filed in a court document does not mean that it is \u8220\'3fnot subject to reasonable dispute.\u8221\'3f
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022038337569_54}{\*\bkmkend co_footnote_B00022038337569_54}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022038337569_ID0EPDAC_54" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Although the factual recitation contains some citations to materials that are outside the scope of the Complaint, those citations are for background purposes only and are not relied on by the Court in assessing defendant\rquote s motion to dismiss.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00032038337569_54}{\*\bkmkend co_footnote_B00032038337569_54}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00032038337569_ID0EKIAC_54" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
3
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
For ease of reference, the Court uses the phrase \u8220\'3fblood\u8221\'3f or \u8220\'3fblood sample\u8221\'3f to include \u8220\'3fblood, serum, plasma, blood 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iadf4fbaa475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
leukocytes
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 selected from the group consisting of neutrophils, monocytes, subpopulations of neutrophils, and subpopulations of monocytes, or any combination thereon.\u8221\'3f
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00042038337569_54}{\*\bkmkend co_footnote_B00042038337569_54}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00042038337569_ID0E1LAE_54" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
4
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Plaintiff notes in its motion that claim 18 contains the \u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic59c47f7475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
immunological technique
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8221\'3f limitation. (Doc. 30 at p. 5). No such limitation appears in claim 18.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00052038337569_54}{\*\bkmkend co_footnote_B00052038337569_54}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00052038337569_ID0EDHAG_54" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
5
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The Court has reviewed each of the representative patent claims in all three of the patents. Each claim, however, contains no step or combination of steps that contain an inventive element. Rather, all representative claims contain combinations of the \u8220\'3fcomparing\u8221\'3f or \u8220\'3fdetermining\u8221\'3f limitations that, when read in combination, do not amount to an inventive concept.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00062038337569_54}{\*\bkmkend co_footnote_B00062038337569_54}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00062038337569_ID0ETJAG_54" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
6
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Defendant argues that the prior art shows that, contrary to plaintiff\rquote s position, it was 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
not 
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
the first to look at MPO mass in the blood. Defendant appears correct in this regard. The United States Patent Office (\u8220\'3fUSPTO\u8221\'3f) rejected certain claims in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 552 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 as being anticipated by Minota, which \u8220\'3fteaches detecting MPO mass in blood from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib7c7c8e9475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
vasculitis
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 patients.\u8221\'3f
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00072038337569_54}{\*\bkmkend co_footnote_B00072038337569_54}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00072038337569_ID0ENTAG_54" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
7
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
To the extent plaintiff argues that the patent requires use of a \u8220\'3fnew\u8221\'3f testing kit, the argument is rejected. Nowhere in the claim language does the patent require use of any particular \u8220\'3fnew\u8221\'3f kit.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00082038337569_54}{\*\bkmkend co_footnote_B00082038337569_54}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00082038337569_ID0EIGBG_54" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
8
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
To infringe the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 260 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, the infringer must perform an \u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic7562c94475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
enzyme linked immunosorbent assay
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (ELISA).\u8221\'3f Defendant claims that it does not measure MPO mass or activity in this fashion. The Court notes that it is not accepting defendant\rquote s statement as true for purposes of this motion. Rather, the Court simply notes that plaintiff wholly fails to describe or identify defendant\rquote s role in the alleged \u8220\'3finducement\u8221\'3f of any infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Idce34d30dac311e581b4a1a364f337cb&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 260 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf25 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf25 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf25 \f4 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf25 \f4 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf25 \f4 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf25 \f4 \ri29 \i0 \fs19 \li29 
{\b0 \cf25 \f4 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf25 \f4 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }